{"schema_version":"secwatch.filing_event.v1","accession":"0001410098-26-000020","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2026-05-14T11:34:46+00:00","discovered_at":"2026-05-14T11:40:01.293404+00:00","generated_at":"2026-05-14T11:40:59.694282+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance","bullets":["Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.","DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.","Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.","Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.","Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001410098-26-000020","json":"https://secwatch.observer/filing/0001410098-26-000020.json","markdown":"https://secwatch.observer/filing/0001410098-26-000020.md","text":"https://secwatch.observer/filing/0001410098-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/0001410098-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000141009826000020/crmd-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:40:59.694282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}